Viatris’ Interchangeable Semglee Lands On Express Scripts Formulary

Company To Adopt ‘Dual Product Approach’ With Authorized Version

22 Oct 2021

Months after obtaining the first US FDA designation of interchangeability, for its Semglee biosimilar to Sanofi’s Lantus, Viatris has seen a return on its investment, with the biosimilar scooping preferred status on one of the largest national formularies in the US.

Dollar sign made out of white pills on blue background — Express Scripts estimates cost savings of $20m • Source: Alamy

Viatris Inc. is set to gain a significant commercial boost for its newly-obtained interchangeable biosimilar Semglee (insulin glargine-yfgn), with the product moving to preferred status on pharmacy benefit manager Express Scripts’ largest national formulary from 1 January 2022.

Meanwhile, the US-based player has disclosed for the first time that it will commercialize an authorized interchangeable biosimilar product, under...